Sovihep Tablets

Availability:
Your Name (required) Your Email (required) Mobile No(required) Enter Product name Sovihep Tablets Trade Information Minimum Order Quantity 1.00 Unit of Measure Piece/Pieces Payment Terms Paypal, Others Delivery Time 7-15 Days Packaging Details Carton Boxes Packaging Main Export Market(s) Asia, Australia, Central America, North America, South America, Eastern Europe, Western Europe, Africa Main Domestic Market [...]

Product Description

Sovihep Tablets Trade Information

Minimum Order Quantity 1.00 Unit of Measure Piece/Pieces
Payment Terms Paypal, Others Delivery Time 7-15 Days
Packaging Details Carton Boxes Packaging Main Export Market(s) Asia, Australia, Central America, North America, South America, Eastern Europe, Western Europe, Africa
Main Domestic Market All India Certifications Certified Products.
Export Countries Details Countries: Russsia, Ukrain, Korean, Ajbakistan, Kajistan, Poland, USA, India, Philipines & China

Product Description
These tablets should be used combination with ribavirin or in combination with pegylated interferon. We have been able to attain strong market goodwill as a trusted organization engaged in offering our clients Sovihep Sofosbuvir 400mg Tablets. These tablets are indicated in combination with other medical products for the treatment of chronic hepatitis C in adults. We source these tablets from the trusted and reliable vendors of the market. We offer these Sofosbuvir 400mg Tablets at reasonable prices to clients.

Features:

  • Taken orally
  • Consumed with or without food
  • Low indication of side effects

Buy Sovihep from India Exporters, Suppliers & Distributors

Zydus Sofosbuvir Tablets SoviHep
Product Description

SoviHep tablets are administered orally. Each tablet contains 400 mg.
INDICATIONS AND USAGE
SoviHep is indicated in combination with other medical products for the treatment of chronic hepatitis C (CHC) in adults.
DOSAGES AND ADMINISTRATION
Recommended Dose in adults
The recommended dose of tablets is one 400 mg tablet, taken orally, once daily with or without food SoviHep should be used combination with ribavirin or in combination with pegylated interferon and ribavirin for the treatment of CHC in adults.The recommended regimen and treatment duration for the combination therapy is provided in following table.
Recommended Regimens and Treatments Duration for SoviHep Combination Therapy in HCV Mono-infected and HCH/HIV-1 Co-infected Patients

Treatment Duration
Patients with genotype 1 of 4 CHC SoviHep + peginsterferon alfaa +ribavirinb 12 weeks
Patients with genotype 2 CHC SoviHep+ ribavirinb 12 weeks
Patients with genotype 3 CHC SoviHep+ ribavirinb 24 weeks

Dose Modification
Dose reduction of SoviHep is not recommended.
Genotype 1 and 4:
If a patients has a serious adverse reaction potentially related to peginterferon alfa and /or ribavirin, the peginterferon alfa and/or ribavirin dose should be reduced or discontinued. Refer to the peginterferon alfa and ribavirin prescribing information for the additional information about how to reduce and/or discontinue the peginterferon alfa and/or ribavirin dose.
Genotype 2 and 3:
If a patient has a serious adverse reaction potentially related to ribavirin, the ribavirin dose should be modified or discontinued, if appropriate, until the adverse reaction abates or decreases in sverity.Provides guidelines for dose modifications and discontinuation based on the patient’s hemoglobin concentration and cardiac status.
DOSAGES FORMS AND STRENGTHS
Each film coated tablet of SoviHep 400 mg is available as capsules shaped, brick red colored and debossed with 400 on one side and plain on another side.
CONTRAINDICATIONS
It is used in combination with ribavirin to peginterferon alfa/ribavirin; the contraindications applicable to those agents are applicable to combination therapies. Refer to the prescribing information of peginterferon alfa and ribavirin for a list of their contraindications.
WARNINGS AND PRECAUTIONS
Pregnancy: Use with Ribavirin or Peginterferon Alfa/Ribavirin
Ribavirin may cause birth defects and /or deaths of the exposed fetus and animal have shown that interferons have abortifacient effects. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients. Ribavirin therapy should not be started unless a report of a negative pregnancy test has been obtained immediately prior to initiation of therapy.
When this is used in combinations with ribavirin or peginterferon alfa/ribavirin, women of childbearing potential and their male partners must use two forms of effective contraception during treatment and for at least 6 months after treatment. Monthly pregnancy tests must be performed during this time. There are no data on the effectiveness of systemic hormonal contraceptives in women taking SoviHep therefore, two non-hormonal methods of contraception should be used during treatment with SoviHep and concomitant ribavirin.
ADVERSE REACTIONS
The most common adverse events (>=20%) for SoviHep + ribavirin combination therapy were fatigue and headache. The most common adverse events (>=20%) for SoviHep + peginterferon alfa+ ribavirin combination therapy were fatigue, headache, nausea, insomnia and anemia.